[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100659857":3},{"organization":4,"outcomesModule":7,"designInfo":77,"detailedDescription":76,"studyPopulation":76,"armGroups":86,"interventions":99,"overallOfficials":76,"centralContacts":76,"locations":109,"responsibleParty":123,"collaborators":76,"id":127,"slug":128,"hasResults":129,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":76,"eligibilityCriteria":133,"healthyVolunteers":134,"sex":135,"minAge":136,"maxAge":137,"enrollmentInfo":138,"targetDuration":76,"studyType":141,"phases":142,"briefSummary":144,"conditions":145,"keywords":148,"overallStatus":153,"whyStopped":76,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"Universidade Federal de Santa Maria","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":76},[9,13],{"measure":10,"description":11,"timeFrame":12},"Pain Intensity Assessed by Visual Analog Scale (0-10)","Pain intensity will be assessed using the Visual Analog Scale ranging from 0 to 10; higher scores indicate greater pain.","Pre-intervention, immediately after the intervention, and 24, 48, and 72 hours after the exercise protocol.",{"measure":14,"description":15,"timeFrame":16},"Pressure Pain Threshold Assessed by Digital Pressure Algometry","Pressure pain threshold will be assessed in the wrist flexor and extensor regions using a digital pressure algometer. Three measurements will be obtained and the mean value will be used.","Pre-intervention and immediately after the intervention",[18,22,26,29,32,36,40,43,46,49,52,55,58,61,64,67,70,73],{"measure":19,"description":20,"timeFrame":21},"Perceived Exertion Assessed by Modified Borg Scale (0-10)","Perceived exertion will be assessed using the Modified Borg Scale ranging from 0 to 10, where 0 indicates no exertion\u002Frest and 10 indicates maximal exertion\u002Fexhaustion; higher scores indicate greater perceived exertion.","Immediately after the intervention.",{"measure":23,"description":24,"timeFrame":25},"Handgrip Strength Measured by Manual Dynamometry","Handgrip strength will be assessed using a manual dynamometer. Three measurements will be performed in each hand.","Pre-intervention and immediately after the intervention.",{"measure":27,"description":28,"timeFrame":25},"Range of Motion Assessed by Goniometry","Elbow and wrist range of motion will be assessed using a manual goniometer. Three consecutive measurements will be performed for each movement, and the mean value will be used for analysis.",{"measure":30,"description":31,"timeFrame":25},"Wrist Pain and Function Assessed by the Brazilian Patient Rated Wrist Evaluation (PRWE-BR)","Wrist pain and function will be assessed using the Brazilian version of the Patient Rated Wrist Evaluation (PRWE-BR). The questionnaire contains 15 items, with a total score ranging from 0 to 100; higher scores indicate greater pain or functional limitation.",{"measure":33,"description":34,"timeFrame":35},"Blood Lactate Concentration Assessed Using Reagent Strips","Blood lactate will be assessed using reagent strips.","Immediately after completion of the exercise protocol.",{"measure":37,"description":38,"timeFrame":39},"Serum Tumor Necrosis Factor Alpha (TNF-α) Concentration","Serum TNF-α concentration will be assessed by flow cytometry using the Cytometric Bead Array (CBA) technique.","Baseline and 2 hours after the intervention.",{"measure":41,"description":42,"timeFrame":39},"Serum Interleukin-6 (IL-6) Concentration","Serum IL-6 concentration will be assessed by flow cytometry using the Cytometric Bead Array (CBA) technique.",{"measure":44,"description":45,"timeFrame":39},"Serum Interleukin-10 (IL-10) Concentration","Serum IL-10 concentration will be assessed by flow cytometry using the Cytometric Bead Array (CBA) technique.",{"measure":47,"description":48,"timeFrame":39},"Serum Creatine Kinase (CK) Concentration","Serum creatine kinase concentration will be assessed as a marker of muscle damage.",{"measure":50,"description":51,"timeFrame":39},"Serum Lactate Dehydrogenase (LDH) Concentration","Serum lactate dehydrogenase concentration will be assessed as a marker of muscle damage.",{"measure":53,"description":54,"timeFrame":39},"Serum High-Sensitivity C-Reactive Protein (hs-CRP) Concentration","Serum high-sensitivity C-reactive protein concentration will be assessed as a marker of systemic inflammation.",{"measure":56,"description":57,"timeFrame":39},"Reactive Oxygen Species Production Assessed by H2DCF-DA Fluorescence","Reactive oxygen species production will be determined by oxidation of reduced dichlorofluorescein (H2DCF-DA), with fluorescence quantified using a spectrofluorometer.",{"measure":59,"description":60,"timeFrame":39},"Thiobarbituric Acid Reactive Substances (TBARS) Level Assessed by Spectrophotometry","TBARS levels will be measured spectrophotometrically at 532 nm using an MDA standard curve and corrected for protein content.",{"measure":62,"description":63,"timeFrame":39},"Protein Carbonyl Concentration Assessed by the DNPH Method","Protein carbonyls will be assessed by reaction with 2,4-dinitrophenylhydrazine (DNPH) and measured at 370 nm using a spectrophotometer. Results will be reported as nmol of carbonyls per mg of protein.",{"measure":65,"description":66,"timeFrame":39},"Plasma Total Reactive Antioxidant Potential (TRAP) Assessed by Luminol Luminescence","Plasma total reactive antioxidant potential will be measured by luminescence using 2,2'-azo-bis(2-amidinopropane) and luminol, with Trolox used for calibration.",{"measure":68,"description":69,"timeFrame":39},"Erythrocyte Superoxide Dismutase (SOD) Activity Assessed by Spectrophotometry at 480 nm","Cytosolic Cu\u002FZn superoxide dismutase activity will be measured in erythrocytes using glycine buffer and adrenaline. The reaction will be measured spectrophotometrically at 480 nm, and enzyme activity will be expressed as units of enzymatic activity per mg of protein.",{"measure":71,"description":72,"timeFrame":39},"Glutathione Peroxidase (GPx) Activity Assessed by NADPH-Coupled Spectrophotometry at 340 nm","Glutathione peroxidase activity will be assessed using a glutathione reductase-coupled spectrophotometric assay by monitoring NADPH oxidation at 340 nm.",{"measure":74,"description":75,"timeFrame":39},"Erythrocyte Catalase (CAT) Activity Assessed by Spectrophotometry at 240 nm","Catalase activity will be measured in erythrocytes by kinetic analysis following the addition of hydrogen peroxide, with the reaction measured spectrophotometrically at 240 nm.",null,{"allocation":78,"interventionModel":79,"interventionModelDescription":76,"primaryPurpose":80,"observationalModel":76,"timePerspective":76,"maskingInfo":81},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":82,"maskingDescription":76,"whoMasked":83},"DOUBLE",[84,85],"PARTICIPANT","OUTCOMES_ASSESSOR",[87,93],{"label":88,"type":89,"description":90,"interventionNames":91},"Intervention Group","EXPERIMENTAL","Participants will receive pulsed low-intensity therapeutic ultrasound applied to the wrist flexor and extensor muscle regions.",[92],"Device: Pulsed Low-Intensity Therapeutic Ultrasound",{"label":94,"type":95,"description":96,"interventionNames":97},"Placebo Group","PLACEBO_COMPARATOR","Participants will undergo the same therapeutic ultrasound procedures as the intervention group, including the same positioning, application sites, frequency, duty cycle, movement, and application time, but with the device intensity set to zero.",[98],"Device: Placebo Therapeutic Ultrasound",[100,105],{"type":101,"name":102,"description":103,"armGroupLabels":104,"otherNames":76},"DEVICE","Pulsed Low-Intensity Therapeutic Ultrasound","Pulsed low-intensity therapeutic ultrasound will be applied using a Sonopulse III device at a frequency of 1 MHz, an intensity of 0.4 W\u002Fcm² SATA, and a 20% duty cycle (2 ms on, 8 ms off), resulting in an effective average intensity of 0.08 W\u002Fcm² SATA. The intervention will be applied for 5 minutes to the wrist flexor muscle region and 5 minutes to the wrist extensor muscle region. A conductive ultrasound gel will be used.",[88],{"type":101,"name":106,"description":107,"armGroupLabels":108,"otherNames":76},"Placebo Therapeutic Ultrasound","The placebo procedure will be performed using the same positioning, application sites, frequency, waveform, duty cycle, transducer movements, and application time as the active therapeutic ultrasound intervention, but with the device intensity set to zero.",[94],[110],{"facility":111,"status":76,"city":112,"state":113,"zip":114,"country":115,"countryCode":116,"cosmosGeoPoint":117,"geoPoint":122,"contacts":76},"Physical-Functional Rehabilitation Laboratory, Federal University of Santa Maria","Santa Maria","Rio Grande do Sul","97105-900","Brazil","BR",{"type":118,"coordinates":119},"Point",[120,121],-53.80694,-29.68417,{"lat":121,"lon":120},{"type":124,"investigatorFullName":125,"investigatorTitle":126,"investigatorAffiliation":5,"oldNameTitle":76,"oldOrganization":76},"PRINCIPAL_INVESTIGATOR","Luis Ulisses Signori","Professor","100659857","therapeutic-ultrasound-for-muscle-recovery-after-muscle-fatigue-exercise-100659857",false,"NCT07871942","Therapeutic Ultrasound for Muscle Recovery After Muscle Fatigue Exercise","Effects of Therapeutic Ultrasound on Muscle Recovery After Muscle Fatigue Exercise: A Randomized Clinical Trial","Inclusion Criteria:\n\n* Men and women aged 18 to 45 years.\n* Literate participants.\n* Normotensive participants, defined as systolic blood pressure \\\u003C120 mmHg and diastolic blood pressure \\\u003C80 mmHg.\n* Participants in good physical and mental health.\n\nExclusion Criteria:\n\n* Obesity, defined as body mass index (BMI) \\>30 kg\u002Fm².\n* Smoking.\n* Continuous medication use.\n* Previous diagnosis of rheumatological, metabolic, cardiovascular, neurological, oncological, immunological, or hematological diseases.\n* Psychiatric and\u002For cognitive disorders.\n* Musculoskeletal dysfunction or pain on the day of assessment.\n* Consumption of alcoholic or caffeinated beverages or foods on the day of assessment.\n* Performance of intense physical activity within 48 hours before the assessments.",true,"ALL","18 Years","45 Years",{"count":139,"type":140},30,"ESTIMATED","INTERVENTIONAL",[143],"NA","This randomized, parallel, placebo-controlled, double-blind clinical trial will evaluate the effects of low-intensity therapeutic ultrasound on muscle recovery after a fatiguing handgrip exercise protocol in healthy adults. Eighty volunteers aged 18 to 45 years will be included and assigned to an intervention group or a placebo group.\n\nParticipants will perform a handgrip exercise protocol designed to induce muscle fatigue. The intervention group will receive pulsed low-intensity therapeutic ultrasound applied to the wrist flexor and extensor muscles, while the placebo group will undergo the same procedures with the ultrasound intensity set to zero.\n\nThe main outcome will be pain. Additional outcomes will include muscle strength, perceived exertion, function, range of motion, inflammatory and muscle damage markers, and oxidative stress parameters. Pain will also be assessed 24, 48, and 72 hours after the exercise protocol.",[146,147],"Muscle Fatigue (C23.888.592.612.612)","Delayed Onset Muscle Soreness (DOMS)",[149,150,151,152],"Ultrasonic Therapy","Myalgia","Post-Exercise Recovery Techniques","Inflammation","NOT_YET_RECRUITING","2026-10-06",{"date":156,"type":157},"2026-10-13","ACTUAL",{"date":159,"type":140},"2026-11-01",{"date":161,"type":140},"2028-06-30",{"name":5,"class":6},1]